Senseonics (NYSE:SENS) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Senseonics (NYSE:SENS - Free Report) in a research note released on Sunday morning. The firm issued a sell rating on the stock.

Separately, HC Wainwright restated a "buy" rating and set a $2.00 target price on shares of Senseonics in a report on Friday, November 15th.

Senseonics Trading Down 2.1 %

Shares of SENS stock traded down $0.01 during mid-day trading on Friday, reaching $0.32. 3,192,735 shares of the stock traded hands, compared to its average volume of 5,209,791. The stock's fifty day simple moving average is $0.34 and its two-hundred day simple moving average is $0.39. The company has a market cap of $188.12 million, a price-to-earnings ratio of -2.43 and a beta of 0.79. Senseonics has a 1-year low of $0.28 and a 1-year high of $0.75. The company has a quick ratio of 2.38, a current ratio of 2.47 and a debt-to-equity ratio of 59.17.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Geode Capital Management LLC increased its stake in Senseonics by 3.2% in the 3rd quarter. Geode Capital Management LLC now owns 5,838,396 shares of the company's stock worth $2,042,000 after acquiring an additional 179,103 shares during the last quarter. FMR LLC boosted its holdings in shares of Senseonics by 48,267.2% in the third quarter. FMR LLC now owns 168,318 shares of the company's stock valued at $59,000 after purchasing an additional 167,970 shares during the period. GSA Capital Partners LLP bought a new position in shares of Senseonics during the 3rd quarter worth $117,000. Symmetry Partners LLC purchased a new position in Senseonics during the 3rd quarter valued at about $164,000. Finally, Cubist Systematic Strategies LLC increased its holdings in Senseonics by 25.9% during the second quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company's stock valued at $166,000 after buying an additional 85,501 shares during the period. Hedge funds and other institutional investors own 12.36% of the company's stock.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.